GLP-1 Weight-Loss Drug Hits JD.com at ¥489 per Dose: The Market Shifts from Approval to Commercialization

Presales are not the endgame, but they are a very tangible signal. The competition in weight-loss drugs is shifting from "who gets approved first, who tells the story first" to "who secures the channel first, who drives conversions first, and who achieves repeat purchases first."

This time, the industry sentiment has been stirred not just because there is yet another GLP-1 product, and not merely because a multinational pharmaceutical company has made another move. Rather, it is because the products have begun to transition from regulatory approval documents to real-world transaction scenarios.

Public reports show that the ecnoglutide weight management product, for which Pfizer has obtained commercial rights in mainland China, has appeared on the JD.com platform with a pre-sale page priced at 489 yuan per vial, with shipping starting from April 27; Pfizer acquired the commercial rights for this product in mainland China from Hangzhou Sinoway in February this year.

This is not just a product launch, but more like a clear signal — weight-loss drugs in China are transitioning from the first half dominated by R&D, regulatory approval, and business development (BD), into the more crucial second half focused on distribution channels, payment systems, and operational execution.

What truly pushes weight-loss drugs across a threshold is not the approval itself, but the sales efforts.

As the product begins its presale, the competitive variables shift. The price range is set, the channel entry points are determined, and the shipping schedule is established. The next questions to answer are no longer just "Can this drug be made?" but rather "Will patients want to buy it, can they keep buying it, will channels push it, can the brand be established, and will repeat purchases materialize?" Breaking it down further, the questions get tougher: How high can the initial purchase conversion rate be? Can the customer acquisition cost per person be controlled? Can the repurchase cycle stabilize? And does channel investment bring short-term cash flow or settle into sustained revenue? Pfizer's move to push ecnoglutide into online presales is what truly deserves attention here. It didn't declare who has already won, but it more clearly shifted the focus of observation in China’s GLP-1 track from "talking about the drug" to "selling the drug."

This step may seem small, but it is very significant. The watershed moment in many industries often doesn’t start with a groundbreaking technological breakthrough. Instead, it happens on a certain day when a product finally enters the real world in a way that can be ordered, fulfilled, and repurchased. For weight-loss drugs, this step also means that the market has begun to assess the situation using a model closer to unit economics: Is the cost of traffic too high? Is channel efficiency stable? Can repeat purchases and customer retention cover the initial customer acquisition costs? And is the commercial organization scaling sales or eroding profits?

More intriguing is the way Pfizer has entered the Chinese weight-loss drug market.

It did not start from scratch but quickly entered the market through license-in. Having obtained commercial rights this February, and seeing e-commerce pre-sale pages appear by April, this pace itself indicates that multinational pharmaceutical companies are not shying away from China's obesity market. At least on this product line, Pfizer has chosen to leverage local assets and licensing partnerships to accelerate market entry.

This deal means more than just a single transaction for China's domestic biotech industry.

For a long time, the market's imagination of Chinese innovative pharmaceutical companies has mostly focused on "whether they can create molecules" and "whether they can complete overseas licensing." However, in mature and highly competitive fields like weight-loss drugs, another kind of value is becoming clear: local companies are not just followers; they may also become important gateways for multinational pharmaceutical companies to enter the Chinese market. The collaboration between Pfizer and Sinoway demonstrates at least one thing — the value of China's biotech firms does not have to be realized solely through global rights but can also be achieved through access to the Chinese market, time-to-market advantages, and implementation efficiency. For many biotech companies still in the investment phase, developing a product reflects one capability, while successfully scaling up sales of a weight-loss drug represents an entirely different cost structure and capability. The latter requires more than just the drug itself — it demands continuous investment in channel coverage, patient education, supply assurance, and commercialization infrastructure. For the industry, this may not be the final outcome, but it is certainly a relatively positive signal.

In other words, this news is not just about a drug, but also about a pathway: in the metabolic赛道 (track), a more pragmatic way of connection is forming between global pharmaceutical companies and Chinese assets. The era of storytelling has not ended, but in the end, it still comes back to products, channels, and cash flow. Who will bear the upfront commercialization investment, who will absorb the channel establishment costs, and who will withstand the pressure of thinned profit margins during the market education phase—these questions will hit the books sooner than the concept itself.

More crucially, China's weight-loss drug market already has a sales benchmark for comparison.

Public reports show that in 2025, Novo's Wegovy achieved online sales of approximately 260 million RMB on the Tmall and JD platforms, while Innovent Biologics' Xinermei reached about 416 million RMB in online sales on the same platforms. These figures are far from determining the winner, but they are enough to indicate: this is no longer just a future market confined to research reports; it is a market where actual sales, real competition, and initial differentiation have already begun to take shape.

At this stage, when discussing GLP-1, it is insufficient to only talk about mechanisms, indications, and market potential. The real questions that need answering are more granular and critical: Can patients accept the initial purchase cost? Is their willingness to continue using the medication strong enough? How can in-hospital and out-of-hospital channels be coordinated? How much conversion can online platforms bring? Who can establish stable repeat purchases, and who will be bogged down by price wars, educational costs, and supply pressures? On a deeper level, companies must also answer an even tougher question: Can the growth in sales expenses be offset by matching revenue increments? Can the traffic generated from channel investments translate into substantial repeat purchase income? And ultimately, can the unit price, discount margins, and fulfillment costs generate positive operating leverage?

The hardest accounts in the high-fever track are often overlooked. Approval solves the qualification issue, while sales address the business problem. The former opens up valuation potential, and the latter determines whether that potential can be realized. The real change brought by Pfizer's recent launch is not about creating competition from scratch, but rather pushing competition earlier and more directly toward operational capabilities. Who has higher channel efficiency, stronger patient stickiness, a more solid commercial organization, and the ability to align customer acquisition costs, repurchase rates, and revenue quality in the same direction? The answers will increasingly reflect on the revenue side.

The Chinese weight-loss drug market, of course, is far from settled.

From the background of policy and demand, this track is also entering a more standardized phase. The National Health Commission of China has released the "Guidelines for Adult Obesity Diet Management (2024 Edition)" and issued the "Obesity Diagnosis and Treatment Guidelines (2024 Edition)" in 2024, followed by the issuance of the "Weight Management Guiding Principles (2024 Edition)" at the end of the same year, continuously promoting the standardization of obesity diagnosis and treatment and weight management. In other words, weight management is gradually transitioning from a mere lifestyle issue to a more systematic medical management issue.

The next round of differentiation may not only occur at the molecular level but could also happen earlier in the channels, payment systems, and patient management aspects.

Multinational pharmaceutical companies do not necessarily have a natural advantage, and local companies are not necessarily destined to be at a disadvantage. What truly determines the landscape is probably not who makes the molecule first, but who gets the entire closed-loop system running smoothly first. The ability to take patients from "seeing the product" to "completing the first purchase," then to "forming repeat purchases," and finally to "generating stable revenue quality" will likely decide success or failure earlier than just being the first with a molecule.

Weight-loss drugs, like many chronic disease medications, ultimately compete on long-term strategy. Whoever can effectively integrate pricing design, physician education, patient management, channel outreach, brand awareness, and repurchase mechanisms will have a better chance of turning a popular drug into a long-term success and converting a one-time sales boost into sustained growth. While drug innovation determines the starting point, commercialization capabilities often define the trajectory and final outcome. At the end of the day, the second half of the weight-loss drug race is not about who tells the hottest story first, but who solidifies revenue, smooths out repurchases, and turns front-end investments into realizable cash flow.

Presales are not the final outcome, but they are sufficient to indicate that the competition in China's weight-loss drug sector is no longer just about the speed of research and development.

The real test is just beginning. Only those who can successfully market a drug, retain its presence, and turn it into a sustainable revenue stream are qualified to talk about barriers, platforms, or valuations. Pfizer’s move to put weight-loss drugs on the shelves signals more than just another player entering the market; it highlights that GLP-1 in China is quickly shifting toward a competition of channels, conversions, repurchases, and operational quality. For this industry, this may not signify a cooling of interest but rather an acceleration from high narrative to high realization — from now on, storytelling still matters, but what matters more is turning stories into business.

This Issue's Content

Source of Information

The statements in this article regarding Pfizer's acquisition of the commercial rights to ecnoglutide in mainland China, the appearance of related product pre-sale pages on the JD platform, pre-sale prices and shipping times, as well as the online sales situation of weight loss drugs in China, are mainly based on public reports from Reuters and others; The policy background involving standardized management of obesity, weight management, and dietary guidance in the article is mainly based on publicly released documents by the National Health Commission, such as the "Adult Obesity Dietary Guide (2024 Edition)", "Obesity Diagnosis and Treatment Guide (2024 Edition)" and "Weight Management Guidelines (2024 Edition)". Relevant judgments in the article are industrial analysis and commentary based on publicly available information.

Disclaimer

This article is only based on publicly available information for organization, analysis, and commentary, and does not constitute any form of investment advice, medical advice, or basis for business decisions. The views expressed in the article represent a phased judgment formed based on current public data; the sales of related products, market competition, and industry structure may still change with policies, channels, payment environments, and corporate operational progress. Investment involves risks, and decisions must be made cautiously.

Note: This article is based on the analysis and integration of public information. If there are any errors, please contact us for modification in time.

       Title: 489 Yuan per Shot Listed on JD.com, Weight Loss Drugs Reach the Checkout Counter